Torthaí cuardaigh - Mahmoud Al‐Hawary
- 1 - 2 toradh as 2 á dtaispeáint
-
1
Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma de réir Petros Grivas, Stephanie Daignault, Scott T. Tagawa, David M. Nanus, Walter M. Stadler, Robert Dreicer, Manish Kohli, Daniel P. Petrylak, David J. Vaughn, Kathryn Bylow, Steven Wong, Joseph L. Sottnik, Evan T. Keller, Mahmoud Al‐Hawary, David C. Smith, Maha Hussain
Foilsithe / Cruthaithe 2013Artigo -
2
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma de réir Maha Hussain, Stephanie Daignault, Neeraj Agarwal, Petros Grivas, Arlene O. Siefker‐Radtke, Igor Puzanov, Gary R. MacVicar, Ellis Levine, Sandy Srinivas, Przemyslaw Twardowski, Mario A. Eisenberger, David I. Quinn, Ulka N. Vaishampayan, Evan Y. Yu, Scott J. Dawsey, Kathleen C. Day, Mark L. Day, Mahmoud Al‐Hawary, David C. Smith
Foilsithe / Cruthaithe 2014Artigo
Uirlisí cuardaigh:
Ábhair a bhaineann le hábhar
Cancer
Chemotherapy
Clinical endpoint
Internal medicine
Medicine
Oncology
Progression-free survival
Randomized controlled trial
Surgery
Adverse effect
Alternative medicine
Bevacizumab
Cetuximab
Colorectal cancer
Common Terminology Criteria for Adverse Events
Gastroenterology
Gemcitabine
Mucositis
Pathology
Phases of clinical research
Placebo
Sunitinib
Urology